Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry

Hala T. Borno, Janet E. Cowan, Shoujun Zhao, Jeanette M. Broering, Peter R. Carroll, Charles J. Ryan

Research output: Contribution to journalArticlepeer-review

Abstract

Background: New data is emerging to guide initial treatment of patients with metastatic prostate cancer (CaP). This study utilizes the Cancer of the Prostate Strategic Urologic Research Endeavor registry to evaluate variations in survival based on initial treatment received by men with metastatic disease at diagnosis or after progression. Materials and methods: Cancer of the Prostate Strategic Urologic Research Endeavor is a national registry of men diagnosed with CaP and managed at 43 community, academic, and Veteran's centers. We examined socio-demographic factors, disease biology, initial and subsequent therapy received, and survival among patients who presented with de novo or recurrent metastatic disease stratified by receipt of initial local therapy vs. combined local and hormonal therapy. The outcome was prostate cancer specific mortality (PCSM). We performed Fine and Gray competing risks regression analysis to evaluate the association between timing of metastasis and PCSM, adjusted for age, initial treatment, and subsequent therapy. Results: Of the 14,753 patients diagnosed with CaP from 1990 to 2016, 669 (5%) had metastatic disease. Among the examined patients, 303 (45%) had metastatic disease at diagnosis and 366 (55%) progressed to metastatic disease. Overall, 461 (69%) were ≥65 years old, 582 (87%) had Medicare, and 227 (34%) had an annual income < $30,000. Prostate-specific antigen at diagnosis was >20 ng/ml for 342 (51%) patients and biopsy Gleason grade was ≥4 + 3 for 386 (58%) patients. Among patients with metastatic disease at diagnosis, 31 (10%) received initial local therapy and 272 (90%) received initial hormonal therapy. Among patients who progressed to metastatic disease, 239 (65%) received initial local therapy and 127 (35%) received initial systemic hormonal therapy. Among patients with metastatic disease, the multivariate competing risks model, after adjusting for sociodemographics, marital status, diagnosis year, and comorbidities, revealed a significantly lower risk of PCSM among patients with de novo vs. recurrent metastatic disease (Hazard Ratio 0.66 (95% Confidence Interval 0.51, 0.85) P = 0.002). In the stratified analysis, no difference was seen for patients treated with initial hormonal vs. combined local and hormonal therapy. Conclusions: In this analysis of a nationwide cohort of men treated for CaP with all types of therapy over 25 years, we observed that among men with metastatic CaP, the risk of PCSM was lower for de novo vs. recurrent metastatic disease. Additionally, no difference was observed based on initial treatment with combined local and hormonal therapy vs. hormonal therapy alone.

Original languageEnglish (US)
Pages (from-to)793.e1-793.e11
JournalUrologic Oncology: Seminars and Original Investigations
Volume38
Issue number10
DOIs
StatePublished - Oct 2020

Bibliographical note

Funding Information:
CaPSURE is supported by grant W81XWH-13-2-0074 from the Prostate Cancer Research Program of the US Department of Defense. HTB is funded by the Prostate Cancer Foundation.

Funding Information:
CaPSURE is supported by grant W81XWH-13-2-0074 from the Prostate Cancer Research Program of the US Department of Defense . HTB is funded by the Prostate Cancer Foundation .

Publisher Copyright:
© 2020 Elsevier Inc.

Keywords

  • Bone metastasis
  • Prostate cancer epidemiology
  • Survival

Fingerprint

Dive into the research topics of 'Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry'. Together they form a unique fingerprint.

Cite this